Nasodine Throat Spray Product Launch in Singapore
Filed with ASX · · 3 pages · English
Firebrick Pharma Limited (ASX:FRE) (Company or Firebrick) is very pleased to announce that its first new product – Nasodine® Throat Spray – has been launched in Singapore. This follows successful completion of commercial manufacturing in Australia in November and December 2025, and shipment to Singapore in early January 2026 (refer previous ASX announcement dated 30 October 2025). Nasodine Throat
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Firebrick announces new product Nasodine Throat Spray
- September 2025 Quarterly Activity Report & Appendix 4C
- Firebrick Secures Investment from Philippines Partner
- Firebrick receives $250,000 R&D Tax Incentive
- Appendix 4E and Annual Report 30 June 2025
Later from Firebrick Pharma
- December 2025 Quarterly Activity Report & Appendix 4C
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- Registration Agreement and Approval of Nasodine in Indonesia
- Trading Halt
- Firebrick Secures $1.5 million via Placement
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma